Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Ultrasound Obstet Gynecol ; 47(6): 712-9, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26138446

ABSTRACT

OBJECTIVES: The objectives of this study were to evaluate the efficacy of minimally invasive ablation of high-risk large sacrococcygeal teratomas (SCT) and to compare the efficacy of vascular and interstitial tumor ablation. METHODS: This was a retrospective multicenter study including a cohort of fetuses with high-risk large SCTs between 2004 and 2010. In addition, we performed a systematic literature review of all cases that underwent tumor ablation in order to compare the survival rates after 'vascular' and 'interstitial' ablation. Statistical analysis was conducted using Bayesian methods. RESULTS: In our cohort, a total of 13 fetuses had high-risk large SCT and five of them underwent tumor ablation. The estimated difference in hydrops resolution rate between the fetal intervention and the no fetal intervention groups was 44.6% (95% credibility interval, 1.5 to 81.0%; Pdiff> 0 = 97.9%). The estimated difference in survival rate between the fetal intervention and the no fetal intervention groups was 31.0% (13.9 to 48.1%; Pdiff> 0 = 99.9%). We analyzed our five cases together with 28 cases from the literature and estimated the difference in survival rate between the vascular and interstitial ablation groups as 19.8% (-13.1 to 50.1%; Pdiff> 0 = 88.3%). The estimated difference in hydrops resolution rate between the vascular and the interstitial ablation groups was 36.7% (-5.7 to 72.7%; Pdiff> 0 = 95.5%). CONCLUSION: Minimally invasive surgery seems to improve perinatal outcome in cases of high-risk large fetal SCT. Our findings suggest that 'vascular' ablation may improve outcome and may be more effective than 'interstitial' tumor ablation, but this hypothesis needs further investigation in a larger multicenter prospective study. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.


Subject(s)
Ablation Techniques/methods , Fetal Therapies/methods , Spinal Neoplasms/surgery , Teratoma/surgery , Ablation Techniques/mortality , Cohort Studies , Female , Humans , Minimally Invasive Surgical Procedures/methods , Pregnancy , Retrospective Studies , Sacrococcygeal Region , Survival Analysis , Treatment Outcome
3.
Ultrasound Obstet Gynecol ; 45(6): 683-8, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25158239

ABSTRACT

OBJECTIVE: To evaluate the impact of the presence of a congenital heart anomaly (CHA) and its potential contribution to morbidity and mortality in infants with congenital diaphragmatic hernia (CDH). METHODS: In this retrospective cohort study, prenatal and postnatal data of all newborns diagnosed with CDH between January 2004 and December 2012 in a single center were reviewed. Cases were classified into two groups: those with 'isolated' CDH and those with both CDH and CHA. Patients with CHA were further subclassified into those with a major or minor CHA based on the Risk Adjustment for Congenital Heart Surgery-1 (RACHS-1), and the Society of Thoracic Surgeons-European Association for Cardiothoracic Surgery (STS-EACTS) scoring systems. Patients with associated non-cardiac anomalies, including 'syndromic cases', were excluded from the analysis. Primary and secondary outcomes were survival up to 1 year of age and a need for extracorporeal membrane oxygenation (ECMO), respectively. RESULTS: Of the 180 infants with CDH, 41 were excluded because of the presence of non-cardiac associated anomalies, 118 had isolated CDH and 21 had CDH with CHA (16 with minor and five with major CHA). Receiver-operating characteristics curve analysis demonstrated that the best cut-off for survival was when the score for CHA was ≤ 2 for both RACHS-1 (area under the curve (AUC), 0.74 (P = 0.04); sensitivity, 80.0%; specificity, 87.5%) and STS-EACTS (AUC, 0.83 (P = 0.03); sensitivity, 100%; specificity, 87.5%). Survival rate at 1 year was significantly lower in those with CHD and a major CHA (40.0%; P = 0.04) than in those with isolated CDH (77.1%) and those with CDH and a minor CHA (81.3%). We found no significant differences among the groups with regard to the need for ECMO. CONCLUSIONS: In general, a milder form of CHA does not appear to have a negative impact on the survival of infants with CDH. However, mortality appears to be significantly higher in infants with CDH and a major form of CHA. The scoring systems appear to be useful as predictors for classifying the effects of CHA in this population of patients.


Subject(s)
Heart Defects, Congenital/mortality , Hernias, Diaphragmatic, Congenital/mortality , Extracorporeal Membrane Oxygenation/statistics & numerical data , Heart Defects, Congenital/classification , Heart Defects, Congenital/complications , Hernias, Diaphragmatic, Congenital/complications , Humans , Infant , Infant, Newborn , Kaplan-Meier Estimate , ROC Curve , Retrospective Studies , Sensitivity and Specificity , Survival Rate
5.
Ultrasound Obstet Gynecol ; 42(4): 449-55, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23671033

ABSTRACT

OBJECTIVES: To present two successful cases of fetoscopic release of amniotic bands with umbilical cord involvement and provide a review of the literature on fetal intervention for amniotic band syndrome (ABS). METHODS: Two cases of ABS were considered in conjunction with a review of the literature. A total of 14 fetuses with ABS underwent fetoscopic intervention between 1965 and 2012. Two of the authors independently completed literature searches in PubMed, Ovid and MEDLINE for articles related to ABS. RESULTS: Among 14 cases of ABS (12 published and our own two), 57% and 7% were complicated by preterm premature rupture of membranes and spontaneous preterm birth, respectively. Overall, fetoscopic intervention preserved limb function in 50% (7/14) of cases. Three cases involved intraoperative complications including intra-amniotic bleeding and uterine wall bleeding, and incomplete procedure due to ineffective equipment. CONCLUSION: Fetoscopic release of amniotic bands with minimally invasive surgery may allow preservation of life and/or limb function in cases of ABS. The acceptable functional outcome in 50% of cases is reassuring, although more experience and further studies are needed to determine the selection criteria that will justify the risk of this invasive in-utero therapy for ABS.


Subject(s)
Amniotic Band Syndrome/surgery , Fetoscopy/methods , Laparoscopy/methods , Adult , Amniotic Band Syndrome/diagnosis , Constriction, Pathologic/diagnosis , Constriction, Pathologic/surgery , Female , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Pregnancy , Pregnancy Outcome , Prenatal Care/methods , Ultrasonography, Prenatal , Umbilical Cord , Young Adult
6.
Eur J Obstet Gynecol Reprod Biol ; 168(2): 161-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23398725

ABSTRACT

OBJECTIVES: To investigate the effect of morphine on the reduced uteroplacental perfusion pressure (RUPP) model of pre-eclampsia in rats. STUDY DESIGN: The abdominal aorta and ovarian arteries of pregnant rats were isolated and clipped on gestational day 14. The chronic morphine treatment group received naltrexone 5 mg/kg 1h before each dose of morphine. L-nitromonomethylarginine 2 mg/kg was administrated in the same pattern. The control group received saline 10 ml/kg. Systolic blood pressure, blood urea nitrogen (BUN), creatinine, creatinine clearance, urinary protein, urinary nitrite/nitrate excretion, and fetal and placental weights were determined. RESULTS: Morphine significantly reduced systolic blood pressure, fetal and placental weights, plasma BUN, creatinine and urinary protein in RUPP rats compared with control rats. Urinary nitrite/nitrate excretion and creatinine clearance were significantly increased in response to morphine treatment. CONCLUSION: Morphine reduced blood pressure and improved renal function in the RUPP model of pre-eclampsia, but this was associated with reduced fetal and placental weights.


Subject(s)
Antihypertensive Agents/therapeutic use , Disease Models, Animal , Morphine/therapeutic use , Nitric Oxide/metabolism , Placental Circulation/drug effects , Pre-Eclampsia/drug therapy , Receptors, Opioid, mu/agonists , Animals , Antihypertensive Agents/adverse effects , Antihypertensive Agents/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Female , Fetal Development/drug effects , Kidney/drug effects , Kidney/metabolism , Kidney/physiopathology , Morphine/adverse effects , Morphine/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Nitrates/urine , Nitric Oxide Synthase/antagonists & inhibitors , Nitrites/urine , Placentation/drug effects , Pre-Eclampsia/metabolism , Pre-Eclampsia/physiopathology , Pregnancy , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/antagonists & inhibitors , Renal Insufficiency/etiology , Renal Insufficiency/prevention & control , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...